GB202104715D0 - Identification of clonal neoantigens and uses thereof - Google Patents

Identification of clonal neoantigens and uses thereof

Info

Publication number
GB202104715D0
GB202104715D0 GBGB2104715.4A GB202104715A GB202104715D0 GB 202104715 D0 GB202104715 D0 GB 202104715D0 GB 202104715 A GB202104715 A GB 202104715A GB 202104715 D0 GB202104715 D0 GB 202104715D0
Authority
GB
United Kingdom
Prior art keywords
identification
clonal neoantigens
neoantigens
clonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2104715.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achilles Therapeutics PLC
Original Assignee
Achilles Therapeutics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achilles Therapeutics UK Ltd filed Critical Achilles Therapeutics UK Ltd
Priority to GBGB2104715.4A priority Critical patent/GB202104715D0/en
Publication of GB202104715D0 publication Critical patent/GB202104715D0/en
Priority to EP22720410.4A priority patent/EP4313125A1/en
Priority to IL306136A priority patent/IL306136A/en
Priority to US17/711,372 priority patent/US11504398B2/en
Priority to JP2023558897A priority patent/JP2024513781A/ja
Priority to PCT/EP2022/058793 priority patent/WO2022207925A1/en
Priority to CA3213222A priority patent/CA3213222A1/en
Priority to AU2022251011A priority patent/AU2022251011A1/en
Priority to CN202280026453.4A priority patent/CN117120080A/zh
Priority to KR1020237035334A priority patent/KR20230165259A/ko
Priority to US17/963,665 priority patent/US12548651B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Primary Health Care (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
GBGB2104715.4A 2021-04-01 2021-04-01 Identification of clonal neoantigens and uses thereof Ceased GB202104715D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB2104715.4A GB202104715D0 (en) 2021-04-01 2021-04-01 Identification of clonal neoantigens and uses thereof
KR1020237035334A KR20230165259A (ko) 2021-04-01 2022-04-01 클론성 신항원의 동정 및 이의 용도
JP2023558897A JP2024513781A (ja) 2021-04-01 2022-04-01 クローナルなネオ抗原の同定及びその使用
IL306136A IL306136A (en) 2021-04-01 2022-04-01 Identification of cloned neoantigens and their uses
US17/711,372 US11504398B2 (en) 2021-04-01 2022-04-01 Identification of clonal neoantigens and uses thereof
EP22720410.4A EP4313125A1 (en) 2021-04-01 2022-04-01 Identification of clonal neoantigens and uses thereof
PCT/EP2022/058793 WO2022207925A1 (en) 2021-04-01 2022-04-01 Identification of clonal neoantigens and uses thereof
CA3213222A CA3213222A1 (en) 2021-04-01 2022-04-01 Identification of clonal neoantigens and uses thereof
AU2022251011A AU2022251011A1 (en) 2021-04-01 2022-04-01 Identification of clonal neoantigens and uses thereof
CN202280026453.4A CN117120080A (zh) 2021-04-01 2022-04-01 克隆性新抗原的鉴定及其用途
US17/963,665 US12548651B2 (en) 2021-04-01 2022-10-11 Identification of clonal neoantigens and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2104715.4A GB202104715D0 (en) 2021-04-01 2021-04-01 Identification of clonal neoantigens and uses thereof

Publications (1)

Publication Number Publication Date
GB202104715D0 true GB202104715D0 (en) 2021-05-19

Family

ID=75883641

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2104715.4A Ceased GB202104715D0 (en) 2021-04-01 2021-04-01 Identification of clonal neoantigens and uses thereof

Country Status (10)

Country Link
US (2) US11504398B2 (https=)
EP (1) EP4313125A1 (https=)
JP (1) JP2024513781A (https=)
KR (1) KR20230165259A (https=)
CN (1) CN117120080A (https=)
AU (1) AU2022251011A1 (https=)
CA (1) CA3213222A1 (https=)
GB (1) GB202104715D0 (https=)
IL (1) IL306136A (https=)
WO (1) WO2022207925A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202202880D0 (en) 2022-03-02 2022-04-13 Achilles Therapeutics Uk Ltd Methods for peptide synthesis
GB202205147D0 (en) 2022-04-07 2022-05-25 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
WO2024194208A1 (en) 2023-03-17 2024-09-26 Achilles Therapeutics Uk Limited Prediction of immunogenicity
GB202307096D0 (en) 2023-05-12 2023-06-28 Achilles Therapeutics Uk Ltd Method
WO2024256485A1 (en) 2023-06-15 2024-12-19 Achilles Therapeutics Uk Limited Identification of neoantigen peptides
GB202407727D0 (en) 2024-05-31 2024-07-17 Ucl Business Ltd Reporters constructs, systems and assays

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150197785A1 (en) 2012-08-10 2015-07-16 The Broad Institute, Inc. Methods and apparatus for analyzing and quantifying dna alterations in cancer
EP2983702A2 (en) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015085147A1 (en) * 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US20160310584A1 (en) 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
CN117467603A (zh) 2015-04-27 2024-01-30 癌症研究技术有限公司 治疗癌症的方法
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
ES2861477T3 (es) * 2015-12-03 2021-10-06 Ares Trading Sa Método para determinar la clonalidad celular
WO2018136664A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
US12286678B2 (en) * 2017-03-20 2025-04-29 Ontario Institute For Cancer Research (Oicr) Cancer risk based on tumour clonality
AU2018298971B2 (en) * 2017-07-14 2025-01-23 Cancer Research Technology Limited Analysis of HLA alleles in tumours and the uses thereof
WO2019109086A1 (en) * 2017-12-01 2019-06-06 Illumina, Inc. Methods and systems for determining somatic mutation clonality
IL259392A (en) * 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neoantigens
US11189361B2 (en) * 2018-06-28 2021-11-30 International Business Machines Corporation Functional analysis of time-series phylogenetic tumor evolution tree
CN111785322A (zh) * 2019-12-30 2020-10-16 杭州慕谷基因科技有限公司 一种结肠腺癌基因组变异与肿瘤进化关系的研究方法
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202205147D0 (en) * 2022-04-07 2022-05-25 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof

Also Published As

Publication number Publication date
US20230071113A1 (en) 2023-03-09
US11504398B2 (en) 2022-11-22
US20220323499A1 (en) 2022-10-13
JP2024513781A (ja) 2024-03-27
WO2022207925A1 (en) 2022-10-06
US12548651B2 (en) 2026-02-10
KR20230165259A (ko) 2023-12-05
CN117120080A (zh) 2023-11-24
CA3213222A1 (en) 2022-10-06
IL306136A (en) 2023-11-01
EP4313125A1 (en) 2024-02-07
AU2022251011A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
IL306136A (en) Identification of cloned neoantigens and their uses
IL277146A (en) Amino acid compounds and methods of use
IL282026A (en) Amino acid compounds and methods of use
EP3612965A4 (en) NEOANTIGEN IDENTIFICATION, MANUFACTURING AND USE
IL281426A (en) New conjugates of montelukast and peptides
SG11202108403UA (en) Anti-clec2d antibodies and methods of use thereof
IL288548A (en) Unique identification and authentication of products
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
GB202205147D0 (en) Identification of clonal neoantigens and uses thereof
SG11202106410VA (en) Multiplexed assay and methods of use thereof
IL290741A (en) Antibodies against cd-96 and methods of using them
GB202001571D0 (en) Identification of biomarkers and uses thereof
PT4200018T (pt) Anticorpos anti-par-2 e métodos de uso dos mesmos
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
IL298668B1 (en) Anti-CD200R1 antibodies and methods of using them
EP4168579A4 (en) METHODS FOR IDENTIFYING AND CHARACTERIZING ANELLOVIRUS AND RELATED USES
GB201916020D0 (en) Crispr-mediated identification of biotinylated proteins and chromatin regions
GB2590230B (en) Methods and kits for detection of 11-dehydro-thromboxane B2
IL308260A (en) Antibodies against Tigit and methods of using them
HK40099131A (zh) 克隆性新抗原的鉴定及其用途
SG11202103348TA (en) Systems and methods for identification of optimized protein production and kits therefor
GB2574223B (en) Adhesives and methods of forming adhesives
IL308683A (en) Peptides and methods of use
IL311185A (en) MOG-binding proteins and uses thereof
SG10201900929RA (en) Identification of zones and snapshots through sequence analysis

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)